Lonsurf and Avastin Colorectal Cancer Treatment Market Analysis and Forecast to 2023

DALLAS, March 2, 2015 /PRNewswire/ --

ReportsnReports.com adds Lonsurf and Avastin (Colorectal Cancer) - Forecast and Market Analysis to 2023 research report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the colorectal cancer market.

Colorectal cancer (CRC) is the second leading cause of mortality among cancer patients in the world and is the third most diagnosed cancer globally, and thus represents a huge burden on healthcare systems. This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the colorectal cancer market, with coverage of multiple settings of the disease including neoadjuvant/adjuvant, first-, second-, third-line KRAS wild-type and mutation-positive, and fourth-line metastatic. In terms of targeted treatments, the metastatic CRC treatment landscape is mature, including the branded treatments Avastin (bevacizumab), Avastin (cetuximab), Erbitux (cetuximab), and Vectibix (panitumumab), treatments that have extended the survival of metastatic patients compared to chemotherapy-only regimens. However, high unmet needs remain for the extension of survival of metastatic patients, and particularly those with KRAS mutation-positive disease, for whom the epidermal growth factor receptor (EGFR) inhibitors Avastin, Erbitux and Vectibix are not recommended.

The report "Lonsurf (Colorectal Cancer) - Forecast and Market Analysis to 2023" focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the colorectal cancer market. Taiho Pharmaceutical's Lonsurf (TAS-102) is an oral nucleoside antitumor drug which launched in 2014 for the treatment of chemotherapy-refractive metastatic CRC in Japan. In May 2014, Taiho Pharmaceutical announced that the Phase III RECOURSE trial met its primary outcome of OS and that the company is preparing for regulatory submission in the US and Europe. In October 2014, Taiho announced that Lonsurf has received FDA Fast-Track designation and had initiated rolling NDA submission. This positive outcome follows the announcement in March 2014 that Lonsurf had gained regulatory approval for the treatment of recurrent unresectable locally advanced or metastatic CRC in Japan based on Phase II data. Order a copy of this report at (Prices start at US $ 3495 for a single user PDF) http://www.reportsnreports.com/purchase.aspx?name=320823 .

The report "Avastin (Colorectal Cancer) - Forecast and Market Analysis to 2023" focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the colorectal cancer market, with coverage of multiple settings of the disease including neoadjuvant/adjuvant, first-, second-, third-line KRAS wild-type and mutation-positive, and fourth-line metastatic.  Avastin was the first agent of a new class of drugs that targeted the angiogenesis pathway. The anti-angiogenic agent is a humanized monoclonal IgG1 that binds to vascular endothelial growth factor-A (VEGF-A), preventing the ligand from binding to the VEGF receptor. Inhibition of the VEGF pathway prevents endothelial cells from proliferating and forming the new bloods vessels that are required for the tumor to grow. The drug delivered as a monotherapy is not curative, and must be co-administered with a chemotherapy regimen. Order a copy of this report at (Prices start at US $ 3495 for a single user PDF) http://www.reportsnreports.com/purchase.aspx?name=320815 .

Scope of these reports includes: Overview of Colorectal Cancer, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape; Detailed information on Lonsurf and Avastin including product description, safety and efficacy profiles as well as a SWOT analysis; Sales forecast for Lonsurf and Avastin for the top eight countries from 2013 to 2023; Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and China.

Reasons to buy 

• Understand and capitalize by identifying products that are most likely to ensure a robust return
• Stay ahead of the competition by understanding the changing competitive landscape for Colorectal Cancer
• Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
• Make more informed business decisions from insightful and in-depth analysis of Lonsurf performance
• Obtain sales forecast for Lonsurf from 2013-2023 in top eight countries (the US, France, Germany, Italy, Spain, the UK, Japan and China)

Other Related Reports: 

Erbitux (Colorectal Cancer) - Forecast and Market Analysis to 2023 

In February 2004, Eli Lilly/BMS/Merck KGaA's Erbitux (cetuximab) became the first monoclonal antibody to be approved by the FDA for metastatic CRC. The recombinant chimeric IgG1 monoclonal antibody was the first of a novel class of antibodies that target the EGFR pathway. Overexpression of the epidermal growth factor receptor (EGFR, HER1, c-ErbB-1) is frequent in CRC, where it contributes to activate genes that drive the cell cycle and mitosis. The binding of Erbitux to EGFR inhibits the downstream signaling of the receptor and hence reduces tumor progression and initiates cell cycle arrest. Complete report details available @ http://www.reportsnreports.com/reports/320824-erbitux-colorectal-cancer-forecast-and-market-analysis-to-2023.html .  

Vectibix (Colorectal Cancer) - Forecast and Market Analysis to 2023 

Amgen/Takeda's EGFR antagonist Vectibix (panitumumab) was approved in the US in 2006 as a monotherapy for chemotherapy-refractory, EGFR-expressing, KRAS wild-type metastatic CRC. EU approval followed in 2007, where the agent is also indicated as a treatment for chemotherapy-refractory KRAS wild-type CRC patients, however, EGFR-expression is not specified. Additionally in the EU, the antibody is approved in combination with FOLFOX in the first-line setting, and with FOLFIRI in the second-line setting after progression on a 5-FU regimen. Complete report details available @ http://www.reportsnreports.com/reports/320816-vectibix-colorectal-cancer-forecast-and-market-analysis-to-2023.html .

Zaltrap (Colorectal Cancer) - Forecast and Market Analysis to 2023 

In 2012, Sanofi/Regeneron's Zaltrap (ziv-aflibercept) was approved by the FDA in combination with FOLFIRI for the treatment of metastatic CRC that has become resistant or progressed on prior oxaliplatin-containing combination therapy (FDA, press release, August 3, 2012). This was followed by European approval in February 2013 (Sanofi and Regeneron, press release, February 5, 2013). Complete report details available @ http://www.reportsnreports.com/reports/320819-zaltrap-colorectal-cancer-forecast-and-market-analysis-to-2023.html .

About Us:

ReportsnReports.com is an online market research reports library of 500,000+ reports and in-depth studies of 5000+ micro markets. We provide reports by 100+ publishers on a range of categories and industries.

Connect with Us: 

G+ / Google Plus: https://plus.google.com/u/0/111656568937629536321/posts  

Twitter: http://twitter.com/marketsreports

Facebook: https://www.facebook.com/pages/ReportsnReports/191441427571689

RSS / Feeds: http://www.reportsnreports.com/feed/l-latestreports.xml

Contact:
Ritesh Tiwari
TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252
Tel:  +1-888-391-5441
[email protected]

SOURCE ReportsnReports